Clinical trials: Bladder Cancers
High-risk Non-muscle-invasive Bladder Cancer
A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy
This is a multicenter, open-label, Phase I/II clinical study evaluating the safety, efficacy, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profiles of HS-10566 in patients with high-risk non-muscle-invasive bladder…
- Trial name
- NCT07468851
- Testing
- HS-10566
- Where
- 2 sites in China
- Volunteers
- 180 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Urinary Bladder Cancer
Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma
Estimate the response to modified hypofractionated radiotherapy concurrent with Gemcitabine in urinary bladder cancer patients . Estimate local control, relapse free survival, overall survival and bladder preservation rate.
- Trial name
- NCT04812145
- Testing
- Chemoradiation
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assiut University
Bladder Cancer, Effects of Chemotherapy
Molecular Markers of Chemosensitivity for Bladder Cancer
The purpose of this study is to try to figure out some bio-markers of chemosensitivity for adjuvant chemotherapy for bladder cancer.
- Trial name
- NCT02074241
- Testing
- Expression analysis
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Southwest Hospital, China
Bladder Cancer
Lymph Node Dissection Before or After Cystectomy
The purpose of this study is to compare different ways of performing surgery for bladder cancer. Specifically, the goal is to determine whether it is better to remove the lymph nodes before removing the bladder or after removing…
- Trial name
- LBOACP (NCT05939856)
- Testing
- Lymph node dissection before bladder resection, Lymph node dissection after bladder resection
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Jagiellonian University
Neoplasms
Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer
This study is for patients with cancer who have failed potentially curative treatments or for whose disease a curative treatment does not exist.
- Trial name
- NCT00487786
- Testing
- OGX-427, Docetaxel
- Where
- 3 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Achieve Life Sciences
Bladder Cancer
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with microscopic hematuria.
- Trial name
- NCT03193541
- Where
- 8 sites in United States, Japan
- Volunteers
- 900 people
- Sponsor
- Cedars-Sinai Medical Center
Bladder Cancer
Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
The purpose of this study is to evaluate the efficacy and safety in patients with non-muscle invasive bladder cancer histologically diagnosed to be stage Ta and G1 or G2 and who were randomized into either an EO9 or placebo group…
- Trial name
- NCT01475266
- Testing
- EO9 (Apaziquone)
- Where
- 20 sites in Japan, South Korea
- Volunteers
- 51 people
- Sponsor
- Nippon Kayaku Co., Ltd.
Bladder Cancer, Breast Cancer
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
This clinical trial studies the effect of four different intervention components "tools" on body weight, nutrition, and physical activity in cancer survivors.
- Conditions
- Bladder Cancer, Breast Cancer, Colon Cancer, Endometrial Cancer
- Trial name
- TTBF (NCT05056077)
- Testing
- Counseling, Educational Intervention, Health Education
- Where
- United States
- Volunteers
- 353 people
- Sponsor
- University of California, San Francisco
Bladder (Urothelial, Transitional Cell) Cancer
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
This study intends to explore whether the combination of Clostridium butyricum can improve the current situation of poor anti-PD1 treatment effect in patients with bladder cancer.
- Trial name
- NCT06696742
- Testing
- Clostridium Butyricum Tablets, Cisplatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Muscle-Invasive Bladder Cancer (MIBC), Upper Tract Urothelial Carcinoma
Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer
This prospective observational study evaluates a blood-based circulating tumor DNA (ctDNA) test in patients with muscle-invasive bladder cancer or upper tract urothelial cancer.
- Conditions
- Muscle-Invasive Bladder Cancer (MIBC), Upper Tract Urothelial Carcinoma, Urothelial Carcinoma (UC)
- Trial name
- BLUT-DNA (NCT07756437)
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- AZ Sint-Lucas Gent
Bladder Cancer, CLE
Confocal Laser Endomicroscopy During TransUrethral Resection for Improving BC Diagnosis and Treatment
A prospective monocenter diagnostic accuracy study of Confocal Laser Endomicroscopy (CLE) for Bladder Cancer(BC) to assess two primary objectives: 1.
- Trial name
- CLETUR (NCT05273593)
- Testing
- Confocal Laser Endomicroscopy (CLE)
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Biliary Tract (Intrahepatic, Extrahepatic Cholangiocarcinoma, Gall Bladder) Cancer
Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma
The objective of the trial is to compare Progression free survival between GEMOX (gemcitabine/oxaliplatin)vs XELOX(capecitabine/oxaliplatin)in metastatic or unresectable Biliary tract carcinoma patients.
- Trial name
- NCT01470443
- Testing
- Oxaliplatin
- Where
- South Korea
- Volunteers
- 240 people
- Sponsor
- Samsung Medical Center
Bladder Cancer, Urocystitis
A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China
The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose bladder cancer by comparing with clinical standard method…
- Conditions
- Bladder Cancer, Urocystitis, Urinary Bladder Stone, Urothelial Carcinoma
- Trial name
- NCT05337189
- Testing
- Urine DNA methylation analysis, medical imaging and/or cystoscopy and/or pathological examination
- Where
- China
- Volunteers
- 482 people, healthy volunteers welcome
- Sponsor
- Creative Biosciences (Guangzhou) Co., Ltd.
Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.
- Conditions
- Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive
- Trial name
- NCT06714617
- Testing
- BL-M17D1
- Where
- 9 sites in United States
- Volunteers
- 3 people
- Sponsor
- SystImmune Inc.
Bladder Cancer, Quality of Life
The Use of Remote Monitoring to Improve Patient-Reported Outcomes and Readmission Rates Following Radical Cystectomy
Following radical cystectomy for bladder cancer, nearly two-thirds of patients experience a complication and almost a third are readmitted.
- Trial name
- WATCH (NCT06397040)
- Testing
- provider monitoring and feedback to remote data, participant monitoring of remote data
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Pittsburgh
Solid Tumors
Cardiac Safety Assessment Study of Picoplatin in Solid Tumors
The purpose of this study is to investigate what effects, if any, picoplatin has on the heart rhythm.
- Trial name
- NCT00710697
- Testing
- Picoplatin
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Poniard Pharmaceuticals
Bladder Cancer, Urinary Tract Infection
Chlorhexidine Antiseptic Irrigation of the Bowel Segment During Radical Cystectomy and Urinary Diversion
This is a single arm, interventional pilot study of using chlorhexidine irrigation intra-operatively and post-operatively among patients undergoing radical cystectomy with urinary diversion.
- Trial name
- NCT06689176
- Testing
- Irrisept® Antimicrobial Wound Lavage
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Bladder Cancer
Enhanced Recovery After Radical Cystectomy Study
Prospective non randomized study of two cohorts: usual protocol and the application of accelerated recovery protocol. F/up after discharge, 90 days and thereafter according to protocol of each center. Compliance to be assessed.
- Trial name
- NCT02328417
- Testing
- Consecutive radical cystectomies
- Where
- 12 sites in Spain
- Volunteers
- 241 people
- Sponsor
- Carlos Llorente
Bladder Cancer
Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
Evaluate the treatment of tamoxifen of low/intermediate-risk bladder tumors
- Trial name
- BCTamoxifen (NCT02197897)
- Testing
- Tamoxifen Citrate
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Baylor College of Medicine
Non Muscle Invasive Bladder Cancer
The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection
The goal of this clinical trial is to evaluate the efficacy of using a urine biomarker test to guide the decision-making process regarding the necessity of reTURBT in NMIBC patients.
- Trial name
- NCT06287541
- Testing
- Urine biomarker -Guided without reTURBT
- Where
- China
- Volunteers
- 428 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.